/Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
NEWS
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
PRNewswire
2026/04/27Acquisitions, Mergers and TakeoversLilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)
Ajax Therapeutics
Summary
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more...